

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Wang, et al.	)	Examiner:	Laura Lynne
		)		Stockton
Serial Number:	10/578,951	)		
		)	Group Art Unit:	1626
Filed:	May 10, 2006	)		
		)	Customer Number:	22827
Confirmation No.:	5136	)		
		)	Deposit Account:	04-1403
Title:	Treatment or Prevention of	)		
	Cardiovascular and Respiratory	)		
	Disorders with Novel Substituted	)		
	Cyclic-Amp Specific	)		
	Phosphodiesterase Inhibitors	)		

**RESPONSE TO OFFICE ACTION**

Commissioner for Patents  
 Post Office Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto.

Fee requirements (if any) have been calculated as shown below:

	Claims remaining after amendment		Highest number previously paid for		Present Extra				Additional Fee
Total Effective Claims	38	minus	45	=	0	x	\$ 52	=	\$ <u>0.00</u>
Independent Claims	3	minus	3	=	0	x	\$ 220	=	\$ <u>0.00</u>

☐ A Request for Continued Examination is requested in view of the: (\$810) \$ 0.00

☐ Previously submitted Amendment / Response dated \_\_\_\_\_

☐ Enclosed Amendment / Reply

☐ Enclosed Affidavit(s) / Declaration(s)

☐ Enclosed Information Disclosure Statement

Since Official Action set an original due date of August 28, 2009,  
**PETITION** is hereby made for an extension to cover the date this

response is filed for which the requisite fee is enclosed (1 month \$130;  
2 months \$490; 3 months \$1,110; 4 months \$1,730, 5 months \$2,350      \$ 490.00

If amendment enters proper multiple dependent claim(s) into this application  
for first time, add \$390.00 (per application)      \$ 0.00

If Terminal Disclaimer enclosed, add Rule 20(d) Official Fee (\$140.00)      \$ 0.00

Other: \_\_\_\_\_ \$ 0.00

**SUBTOTAL:** \$ 490.00

If "small entity" verified statement filed ☐ previously,  
☐ herewith, enter one-half (1/2) of subtotal and subtract      - \$ 245.00

**TOTAL FEE ENCLOSED:** \$ 245.00

---

The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (deficiency only) now or hereafter relative to this application and the resulting official document under Rule 20, or credit any overpayment, to our Account No. shown in the heading hereof. This statement does not authorize charge of the issue fee in this case.

**DORITY & MANNING ATTORNEYS AT LAW, P.A.**

**ADDRESS:**

Post Office Box 1449  
Greenville, SC 29602 USA  
Customer ID No.: 22827  
Telephone: (864) 271-1592  
Facsimile: (864) 233-7342

By: Alan R. Marshall Reg. No: 56,405

Signature:  \_\_\_\_\_


Date: October 28, 2009

---

I hereby certify that this correspondence and all attachments and any fee(s) are being electronically transmitted via the internet to the U.S. Patent and Trademark Office using the Electronic Patent Filing System on October 28, 2009.

Suzanne Haynes

(Typed or printed name of person transmitting documents)

 \_\_\_\_\_  
(Signature of person transmitting documents)

**PATENT**  
**ATTORNEY DOCKET NO: USC-194-PCT-US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:	Wang, et al.	)	Examiner:	Stockton, Laura Lynne
		)		
Appl. No:	10/578,951	)	Group Art Unit/T.C:	1626
		)		
Filed:	May 10, 2006	)	Dep. Acct. No:	04-1403
		)		
Title:	Treatment or Prevention of	)	Conf. No:	5136
	Cardiocascular and Respiratory	)		
	Disorders with Novel Substituted	)	Customer ID No:	22827
	Cyclic-AMP Specific	)		
	Phosphodiesterase Inhibitors	)		

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

**AMENDMENT**

Dear Sir:

In response to the Office Action mailed May 28, 2009, Applicants respectfully request reconsideration and allowance in view of the following:

**Amendments to the Specification** begin on page 2.

**Amendments to the Claims** begin on page 3.

**Remarks** begin on page 10.